Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.48 |
| ▸ | KDR | P35968 | 11/20 | 0.48 |
| ▸ | FLT1 | P17948 | 7/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.48 |
| ▸ | RET | P07949 | 7/20 | 0.47 |
| ▸ | KIF5B | P33176 | 7/20 | 0.47 |
| ▸ | FLT4 | P35916 | 3/20 | 0.47 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.43 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21616332 | 1.00 | EGFR (0.48) | EGFRKDRFLT1FGFR1RET | |
| SCHEMBL23355432 | 0.92 | EGFR (0.47) | EGFRKDRFLT1FGFR1RET | |
| SCHEMBL24037410 | 0.91 | KDR (0.52) | EGFRKDRFLT1FGFR1RET | |
| SCHEMBL23368026 | 0.90 | EGFR (0.48) | EGFRKDRFLT1FGFR1RET | |
| SCHEMBL23368182 | 0.90 | EGFR (0.47) | EGFRKDRFLT1FGFR1RET | |
| SCHEMBL21616281 | 0.87 | EGFR (0.49) | EGFRKDRFLT1FGFR1RET | |
| SCHEMBL24037409 | 0.86 | EGFR (0.48) | EGFRKDRFLT1FGFR1RET | |
| SCHEMBL23368220 | 0.85 | EGFR (0.49) | EGFRKDRFLT1FGFR1RET | |
| SCHEMBL21616334 | 0.85 | EGFR (0.48) | EGFRKDRFLT1FGFR1RET | |
| SCHEMBL23355452 | 0.84 | EGFR (0.47) | EGFRKDRFLT1FGFR1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025510-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025510-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES | ERBB2, EGFR, ERBB3 | EGFR 2/4885KDR 20/4885FLT1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.